Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Impact of Clonal Heterogeneity in Newly Diagnosed, Transplant-Eligible Multiple Myeloma - Subgroup Analysis of the GMMG HD6 Phase III Trial

Blood (2024) 144 (Supplement 1): 84.

https://doi.org/10.1182/blood-2024-201972

Published: 2024

Journal Articles

Elotuzumab in Combination with Lenalidomide, Bortezomib, Dexamethasone and Autologous Transplantation for Newly-Diagnosed Multiple Myeloma: Results from the Randomized Phase III GMMG-HD6 Trial

Blood (2021) 138 (Supplement 1): 486.

https://doi.org/10.1182/blood-2021-147323

Published: 2021

Journal Articles

Response-Adapted Lenalidomide Maintenance in Newly Diagnosed, Transplant-Eligible Multiple Myeloma: Results from the Multicenter Phase III GMMG-MM5 Trial

Blood (2017) 130 (Supplement 1): 400.

https://doi.org/10.1182/blood.V130.Suppl_1.400.400

Published: 2017

Journal Articles

Direct Assessment of IgA and IgG Paraprotein By Hevylite Assay and Correlation to IMWG Response and Progression-Free Survival in Newly Diagnosed, Transplant-Eligible Multiple Myeloma Patients in the Prospective Phase III GMMG-MM5 Trial

Blood (2017) 130 (Supplement 1): 1784.

https://doi.org/10.1182/blood.V130.Suppl_1.1784.1784

Published: 2017

Journal Articles

Addition of Cyclophosphamide to Pomalidomide and Dexamethasone in Case of Suboptimal Response to Pomalidomide and Dexamethasone Alone in Relapsed and/or Refractory Multiple Myeloma: Results of the GMMG-Perspective Trial

Katja C. Weisel, Hans Jürgen Salwender, Christof Scheid, MD, Manola Zago, Britta Besemer, Mathias Hänel, MD, Jan Dürig, MD, Markus Munder, MD, Hans-Walter Lindemann, Anja Seckinger, Christina Kunz, Axel Benner, Dirk Hose, MD, Anna Jauch, Lothar Kanz, Hartmut Goldschmidt, MD

Blood (2017) 130 (Supplement 1): 1849.

https://doi.org/10.1182/blood.V130.Suppl_1.1849.1849

Published: 2017

Journal Articles

Marker chromosomes can arise from chromothripsis and predict adverse prognosis in acute myeloid leukemia

Tilmann Bochtler, Martin Granzow, Friedrich Stölzel, Christina Kunz, Brigitte Mohr, Mutlu Kartal-Kaess, Katrin Hinderhofer, Christoph E. Heilig, Michael Kramer, Christian Thiede, Volker Endris, Martina Kirchner, Albrecht Stenzinger, Axel Benner, Martin Bornhäuser, Gerhard Ehninger, Anthony D. Ho, Anna Jauch, Alwin Krämer

Blood (2017) 129 (10): 1333–1342.

https://doi.org/10.1182/blood-2016-09-738161

Published: 2017

Includes: Supplemental data

Journal Articles

Marker Chromosomes Can Arise from Chromothripsis and Predict Adverse Prognosis in Acute Myeloid Leukemia

Tilmann Bochtler, MD, Martin Granzow, PhD, Friedrich Stölzel, MD, Christina Kunz, PhD, Brigitte Mohr, PhD, Mutlu Kartal-Kaess, MD, Johannes W.G. Janssen, PhD, Christoph E. Heilig, MD, Michael Kramer, MSc, Christian Thiede, MD, Axel Benner, Martin Bornhäuser, MD, Gerhard Ehninger, MD, Anthony D. Ho, MD, Anna Jauch, PhD, Alwin Krämer, MD

Blood (2016) 128 (22): 2869.

https://doi.org/10.1182/blood.V128.22.2869.2869

Published: 2016

Journal Articles

Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study

Tilmann Bochtler, Ute Hegenbart, Christina Kunz, Axel Benner, Christoph Kimmich, Anja Seckinger, Dirk Hose, Hartmut Goldschmidt, Martin Granzow, Peter Dreger, Anthony D. Ho, Anna Jauch, Stefan O. Schönland

Blood (2016) 128 (4): 594–602.

https://doi.org/10.1182/blood-2015-10-676361

Published: 2016

Includes: Supplemental data

Journal Articles

Clinical Risk Factors for Peripheral Neuropathy in Patients Treated with Subcutaneous or Intravenous Bortezomib for Newly Diagnosed Multiple Myeloma

Maximilian Merz, MD, Hans-Juergen Salwender, MD, Mathias Haenel, MD, Uta Bertsch, MD, Christina Kunz, Thomas Hielscher, Igor W. Blau, MD, Christof Scheid, MDPhD, Elias Karl Mai, MD, Dirk Hose, MD, Bärbel Schurich, Markus Munder, MD, Peter Brossart, MD, Christian Gerecke, MD, Hans Walter Lindemann, MD, Matthias Zeis, MD, Katja C. Weisel, Jan Duerig, MD, Hartmut Goldschmidt, MD

Blood (2015) 126 (23): 4233.

https://doi.org/10.1182/blood.V126.23.4233.4233

Published: 2015

Journal Articles

Impact of Severe Infections during Induction Therapy on Dosage, Response and Survival in Newly Diagnosed Multiple Myeloma - a Subgroup Analysis from the Randomized Phase III Trial GMMG-HD4

Elias Karl Mai, MD, Christina Kunz, PhD, Uta Bertsch, MD, Hans-Juergen Salwender, MD, Michael Pfreundschuh, MD, Ulrich Duehrsen, MD, Peter Brossart, MD, Norma Peter, MD, Kai Neben, MD, Thomas Hielscher, Jens Hillengass, MD, Hans Martin, MD, Hans Walter Lindemann, MD, Christof Scheid, MD PhD, Katja C. Weisel, Igor W. Blau, MD, Hartmut Goldschmidt, MD

Blood (2015) 126 (23): 3187.

https://doi.org/10.1182/blood.V126.23.3187.3187

Published: 2015

Journal Articles

Influence of Renal Impairment and Genetic Risk Factors on Response to Induction Therapy in the HD4 and MM5 Trials of the GMMG

Christof Scheid, MDPhD, Thomas Hielscher, Uta Bertsch, MD, Christina Kunz, PhD, Hans Salwender, MD, Mathias Haenel, Maximilian Merz, Elias Karl Mai, MD, Dirk Hose, MD PhD, Baerbel Schurich, PhD, Markus Munder, MD, Ingo Schmidt-Wolf, MD, Christian Gerecke, MD, Walter Lindemann, MD, Matthias Zeis, MD, Katja Weisel, MD, Jan Duerig, MD, Anna Jauch, PhD, Hartmut Goldschmidt, MD

Blood (2014) 124 (21): 4777.

https://doi.org/10.1182/blood.V124.21.4777.4777

Published: 2014

Journal Articles

Subcutaneous Versus Intravenous Bortezomib in Two Different Induction Therapies for Newly Diagnosed Multiple Myeloma – Subgroup Analysis from the GMMG-MM5 Trial

Maximilian Merz, MD, Hans Salwender, MD, Mathias Hänel, MD, Uta Bertsch, MD, Christina Kunz, PhD, Thomas Hielscher, Igor W. Blau, MD, Christof Scheid, MDPhD, Elias Karl Mai, MD, Dirk Hose, MD, Baerbel Schurich, PhD, Markus Munder, MD, Ingo GH Schmidt-Wolf, MD, Christian Gerecke, MD, Hans Walter Lindemann, MD, Matthias Zeis, MD, Katja Weisel, MD, Jan Duerig, MD, Hartmut Goldschmidt, MD

Blood (2014) 124 (21): 3475.

https://doi.org/10.1182/blood.V124.21.3475.3475

Published: 2014

Journal Articles

Impact of Radiation Therapy on Stem Cell Harvest in Multiple Myeloma

Sandra Sauer, Andreas Marco Fischer, Andrea Fraenzle, Christina Kunz, PhD, Maximilian Merz, MD, Patrick Wuchter, Martina Schmaus, Anthony D. Ho, Prof., MD FRCPC, Hartmut Goldschmidt, MD, Jens Hillengass, MD

Blood (2014) 124 (21): 5822.

https://doi.org/10.1182/blood.V124.21.5822.5822

Published: 2014

Journal Articles

Prognostic Significance Of Parameters Of Dynamic Contrast-Enhanced MRI Detecting Increased Bone Marrow Microcirculation In Monoclonal Plasma Cell Disorders

Jens Hillengass, MD, Judith Ritsch, Maximilian Merz, MD, Hartmut Goldschmidt, MD, Christina Kunz, PhD, Barbara Wagner-Gund, Anthony Ho, MD, Thomas M. Moehler, MD, Stefan Delorme, MD

Blood (2013) 122 (21): 3146.

https://doi.org/10.1182/blood.V122.21.3146.3146

Published: 2013

Journal Articles

GMMG MM5 Trial In Newly Diagnosed Multiple Myeloma To Evaluate PAd Vs VCD Induction Prior To High Dose Treatment Followed By Lenalidomide Consolidation and Maintenance – Final Analysis On Induction Therapy

Blood (2013) 122 (21): 3369.

https://doi.org/10.1182/blood.V122.21.3369.3369

Published: 2013

Journal Articles

Prognostic Value Of sFLC Ratio At Baseline On Response After Induction Therapy In Patients With Multiple Myeloma In The GMMG MM5 Trial

Blood (2013) 122 (21): 1897.

https://doi.org/10.1182/blood.V122.21.1897.1897

Published: 2013

NARROW

Impact of Clonal Heterogeneity in Newly Diagnosed, Transplant-Eligible Multiple Myeloma - Subgroup Analysis of the GMMG HD6 Phase III Trial

Elotuzumab in Combination with Lenalidomide, Bortezomib, Dexamethasone and Autologous Transplantation for Newly-Diagnosed Multiple Myeloma: Results from the Randomized Phase III GMMG-HD6 Trial

Response-Adapted Lenalidomide Maintenance in Newly Diagnosed, Transplant-Eligible Multiple Myeloma: Results from the Multicenter Phase III GMMG-MM5 Trial

Direct Assessment of IgA and IgG Paraprotein By Hevylite Assay and Correlation to IMWG Response and Progression-Free Survival in Newly Diagnosed, Transplant-Eligible Multiple Myeloma Patients in the Prospective Phase III GMMG-MM5 Trial

Addition of Cyclophosphamide to Pomalidomide and Dexamethasone in Case of Suboptimal Response to Pomalidomide and Dexamethasone Alone in Relapsed and/or Refractory Multiple Myeloma: Results of the GMMG-Perspective Trial

Marker chromosomes can arise from chromothripsis and predict adverse prognosis in acute myeloid leukemia

Marker Chromosomes Can Arise from Chromothripsis and Predict Adverse Prognosis in Acute Myeloid Leukemia

Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study

Clinical Risk Factors for Peripheral Neuropathy in Patients Treated with Subcutaneous or Intravenous Bortezomib for Newly Diagnosed Multiple Myeloma

Impact of Severe Infections during Induction Therapy on Dosage, Response and Survival in Newly Diagnosed Multiple Myeloma - a Subgroup Analysis from the Randomized Phase III Trial GMMG-HD4

Influence of Renal Impairment and Genetic Risk Factors on Response to Induction Therapy in the HD4 and MM5 Trials of the GMMG

Subcutaneous Versus Intravenous Bortezomib in Two Different Induction Therapies for Newly Diagnosed Multiple Myeloma – Subgroup Analysis from the GMMG-MM5 Trial

Impact of Radiation Therapy on Stem Cell Harvest in Multiple Myeloma

Prognostic Significance Of Parameters Of Dynamic Contrast-Enhanced MRI Detecting Increased Bone Marrow Microcirculation In Monoclonal Plasma Cell Disorders

GMMG MM5 Trial In Newly Diagnosed Multiple Myeloma To Evaluate PAd Vs VCD Induction Prior To High Dose Treatment Followed By Lenalidomide Consolidation and Maintenance – Final Analysis On Induction Therapy

Prognostic Value Of sFLC Ratio At Baseline On Response After Induction Therapy In Patients With Multiple Myeloma In The GMMG MM5 Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only